“Efficacy of Deucravacitinib, an Oral, Selective, Allosteric Tyrosine Kinase 2 (TYK2) Inhibitor, in Scalp Psoriasis by Baseline Psoriasis Area and Severity Index (PASI) and Baseline Body Surface Area (BSA): A Subanalysis of the Phase 3 Clinical Trial Data ”. SKIN The Journal of Cutaneous Medicine 8, no. 4 (July 23, 2024): s405. Accessed April 30, 2026. https://skin.dermsquared.com/skin/article/view/2855.